F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology.
Financial terms were not disclosed. Immuno-oncology leverages the power of the body’s natural immune response to fight cancer. Combination immunotherapies are showing particular promise as cancer therapies, even compared to the advances made with monoclonal antibodies. As the field develops further, bispecific antibodies have the potential for further
improved potency, safety profile and cost efficiency compared to combination therapies.
